Corcept Therapeutics Incorporated (NASDAQ:CORT) shares saw unusually-high trading volume on Tuesday . Approximately 14,181,153 shares traded hands during trading, an increase of 1,087% from the previous session’s volume of 1,194,304 shares.The stock last traded at $18.79 and had previously closed at $17.89.

CORT has been the topic of a number of analyst reports. Piper Jaffray Companies raised their target price on shares of Corcept Therapeutics from $18.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday, September 8th. Stifel Nicolaus initiated coverage on shares of Corcept Therapeutics in a research report on Thursday, August 31st. They set a “buy” rating and a $20.00 target price on the stock. BidaskClub upgraded shares of Corcept Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, December 14th. Finally, Zacks Investment Research lowered shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $21.00.

The stock has a market capitalization of $2,080.00, a P/E ratio of 60.76 and a beta of 1.89.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported $0.11 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.13 by ($0.02). The company had revenue of $42.70 million for the quarter, compared to analysts’ expectations of $41.64 million. Corcept Therapeutics had a return on equity of 72.39% and a net margin of 32.17%. The business’s revenue for the quarter was up 96.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.02 EPS. sell-side analysts forecast that Corcept Therapeutics Incorporated will post 0.47 earnings per share for the current fiscal year.

In other news, Director G Leonard Baker, Jr. sold 30,000 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $17.59, for a total value of $527,700.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Robert S. Fishman sold 8,000 shares of the firm’s stock in a transaction on Friday, December 8th. The shares were sold at an average price of $16.72, for a total transaction of $133,760.00. Following the completion of the transaction, the insider now directly owns 8,000 shares in the company, valued at approximately $133,760. The disclosure for this sale can be found here. Company insiders own 19.20% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Suntrust Banks Inc. increased its stake in Corcept Therapeutics by 4.0% during the 2nd quarter. Suntrust Banks Inc. now owns 12,308 shares of the biotechnology company’s stock worth $145,000 after buying an additional 471 shares during the period. TIAA CREF Investment Management LLC increased its stake in Corcept Therapeutics by 0.7% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 347,171 shares of the biotechnology company’s stock worth $4,097,000 after buying an additional 2,360 shares during the period. PNC Financial Services Group Inc. increased its stake in Corcept Therapeutics by 52.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 9,837 shares of the biotechnology company’s stock worth $116,000 after buying an additional 3,390 shares during the period. American International Group Inc. increased its stake in Corcept Therapeutics by 8.1% during the 3rd quarter. American International Group Inc. now owns 61,110 shares of the biotechnology company’s stock worth $1,179,000 after buying an additional 4,569 shares during the period. Finally, State Board of Administration of Florida Retirement System increased its stake in Corcept Therapeutics by 13.0% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 44,813 shares of the biotechnology company’s stock worth $865,000 after buying an additional 5,150 shares during the period. 64.64% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Corcept Therapeutics (CORT) Sees Large Volume Increase” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://theolympiareport.com/2017/12/28/corcept-therapeutics-cort-sees-large-volume-increase.html.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.